Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Brokerages give Abeona Therapeutics a consensus rating of “Moderate Buy” (four buy ratings, one sell) with an average 1‑year price target of $19.00.
• The stock opened at $5.43, has a market cap of about $308.9M, a 52‑week range of $4.00–$7.54, and a P/E of 5.27 with 50‑ and 200‑day moving averages near $5.00.
• In the last quarter Abeona reported EPS of ($0.34), beating estimates by $0.01 but missing on revenue ($3.0M vs. $5.65M expected), and analysts forecast roughly ‑0.6 EPS for the current fiscal year.

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $19.00.

A number of equities research analysts recently issued reports on the stock. Stifel Nicolaus set a $17.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, March 17th. Oppenheimer reissued an "outperform" rating on shares of Abeona Therapeutics in a research note on Monday, March 9th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Abeona Therapeutics in a research note on Thursday, March 19th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st.

Abeona Therapeutics Price Performance

Abeona Therapeutics stock opened at $5.43 on Monday. The company's fifty day moving average price is $4.98 and its 200 day moving average price is $5.02. Abeona Therapeutics has a 1 year low of $4.00 and a 1 year high of $7.54. The stock has a market capitalization of $308.86 million, a P/E ratio of 5.27 and a beta of 1.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.74 and a current ratio of 6.93.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings results on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.01. The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $5.65 million. As a group, equities research analysts anticipate that Abeona Therapeutics will post -0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new stake in Abeona Therapeutics during the 2nd quarter worth $27,000. Russell Investments Group Ltd. purchased a new stake in shares of Abeona Therapeutics in the third quarter valued at approximately $37,000. Truvestments Capital LLC increased its holdings in shares of Abeona Therapeutics by 191.4% in the fourth quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 6,770 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at approximately $57,000. Finally, Legato Capital Management LLC acquired a new stake in shares of Abeona Therapeutics in the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.